GSK5764227: An Antibody-Drug Conjugate Targeting B7-H3 Enters Phase 1/2 Trial

/in , , , /by

GSK5764227 represents a promising advancement in treating metastatic castration-resistant prostate cancer (mCRPC). This antibody-drug conjugate targets B7-H3, a protein overexpressed on prostate cancer cells, delivering a topoisomerase I inhibitor payload directly to tumors while minimizing damage to healthy tissues. Early data from broader solid tumor studies show the drug’s monotherapy potential, with objective response rates […]

Read more

MHB048C: A New PSMA-Targeted Therapy for Advanced Solid Tumors

/in , , , /by

MHB048C is an investigational antibody–drug conjugate designed to target prostate‑specific membrane antigen (PSMA) on tumor cells and selectively deliver a DNA topoisomerase I–inhibiting cytotoxic payload. By combining a PSMA‑directed antibody with a potent payload, the drug aims to exploit the high and relatively restricted expression of this surface antigen in advanced prostate cancer and in […]

Read more

CONVERT‑HB1: a Phase 2 Trial About Prostate Directed Treatment After Systemic Treatment in mHSPC

/in , , /by

CONVERT‑HB1 trial addresses a long‑standing uncertainty in metastatic hormone‑sensitive prostate cancer: whether aggressively treating the primary prostate tumor adds meaningful benefit for patients who already have high‑volume metastatic disease and are receiving modern intensified systemic therapy. For years, data from studies like STAMPEDE and HORRAD suggested that local treatment to the prostate might help men […]

Read more

UPDATE: TD001 a New Potent ADC for Prostate Cancer Expressing PSMA Enters Phase 1/2

/in , , , /by

TD001, is an investigational antibody-drug conjugate directed against prostate-specific membrane antigen (PSMA), developed for the treatment of men with metastatic castration-resistant prostate cancer whose tumors express PSMA will start recruiting patients for its phase 1/2 clinical trial. Mechanistically, TD001 combines a monoclonal antibody directed against PSMA with a topoisomerase I inhibitor payload, exatecan, linked through […]

Read more

REVELUTION Trial: GnRH Antagonists Show Less Coronary Plaque Progression Than Agonists in Prostate Cancer ADT

/in , , /by

Relugolix showed less coronary plaque progression than leuprolide in men receiving androgen deprivation therapy with prostate cancer and pelvic radiotherapy, according to the REVELUTION trial. The prospective study enrolled 94 ADT-naïve men from June 2022 to March 2024, with 90 completing analysis across three arms: radiotherapy alone (n=28), radiotherapy plus leuprolide (n=31), and radiotherapy plus […]

Read more

Phase 2 Trial for The Combo Fasudil Hydrochloride Plus PD-1 Immune Checkpoint Blockade

/in , , /by

A clinical trial at Zhongda Hospital in China is testing a combination of fasudil hydrochloride, a Rho-associated kinase (ROCK) inhibitor, with PD-1 immune checkpoint blockade in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). This Phase II open-label trial enrolls patients aged 18 to 85 years who have progressed after at least one docetaxel-containing chemotherapy […]

Read more

Phase 1/2 Trial: Valemetostat Plus Darolutamide in mCRPC

/in , , , /by

A phase 1/2 clinical trial investigating valemetostat (DS-3201b), a dual EZH1/2 inhibitor, combined with darolutamide in metastatic castration-resistant prostate cancer (mCRPC) is going to start to recruit participants. This study aims to evaluate the safety, tolerability, and preliminary efficacy of the combination in men whose disease has progressed despite prior androgen receptor pathway inhibitors (ARPIs). […]

Read more

Phase 2 Trial For a New Triplet Therapy: SHR3680 (Rezvilutamide), HS-20093 and SHR2554

/in , , /by

This Phase II study investigates the efficacy and safety of three investigational agents: SHR3680 (rezvilutamide), HS-20093, and SHR2554, aiming to enhance outcomes in metastatic prostate cancer through dual-pathway inhibition. SHR3680, a selective androgen receptor (AR) antagonist, represents the latest generation of hormonal therapy designed to inhibit the AR signaling axis, a critical driver of prostate […]

Read more

EVOLUTION Trial Ipilimumab And Nivolumab Plus 177Lu‑PSMA‑617 in mCRPC

/in , , /by

Phase II EVOLUTION is a randomized study testing whether adding ipilimumab and nivolumab to 177Lu‑PSMA‑617 improves outcomes versus 177Lu‑PSMA‑617 alone in men with metastatic castration‑resistant prostate cancer (mCRPC). Early data presented in 2025 indicate that at 12 months, 33% of patients on the combination were free of progression versus 17% on 177Lu‑PSMA‑617 alone, signaling a […]

Read more

New Trial for AMO959 and Pluvicto and ARSI Combo

/in , , , /by

The ongoing phase Ib/II trial investigating the combination of AMO959, Pluvicto (lutetium-177 vipivotide tetraxetan, also known as AAA617 or 177Lu-PSMA-617), and androgen receptor pathway inhibitors (ARPIs) in metastatic castration-resistant prostate cancer (mCRPC) explores a novel approach targeting disease through multiple pathways. AMO959 is a direct activator of AMPK, a key metabolic regulator that can disrupt […]

Read more